Related Experiment Video
Updated: Jul 8, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Oxaliplatin-induced immune mediated thrombocytopenia
Muhammad S Beg1, Rami S Komrokji, Kashif Ahmed
1Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Abstract:
Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drug toxicity: Idiosyncratic Reactions
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists